The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Share News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Regent Pacific To Acquire Plethora Solutions For GBP114.3 Million

Tue, 15th Dec 2015 13:47

LONDON (Alliance News) - Regent Pacific Group Ltd on Tuesday said it has agreed to acquire the shares it doesn't already own in Plethora Solutions Holdings PLC, valuing the premature ejaculation treatment company at 11.65 pence per share.

The deal values Plethora at about GBP95.9 million, based on the number of shares in issue, and at GBP114.3 million when considering its fully diluted share capital. Shareholders in Plethora will receive 15.7076 new Regent Pacific shares for each Plethora share they own. Shares in Plethora jumped by 18% to 5.30p on Tuesday afternoon.

The deal comes about six weeks after the companies said they had agreed on the key terms of a possible deal.

James Mellon is the non-executive chairman of Plethora and non-executive co-chairman of Regent Pacific, and Jamie Gibson is an executive director and the chief executive of both companies. Plethora's main product is PSD502, a treatment for premature ejaculation.

On completion of the offer, Plethora shareholders other than Regent Pacific will own about 65.98% of the combined group.

"This offer is about optimising growth and realising the potential of an innovative product that can address a known medical condition affecting almost one in four men. With increased investment and commercial innovation, we see huge scope for the product initially in Europe where it has approval, and in the important US market and in the fast growing Asian market in due course," James Mellon said.

"We view the offer as taking account of PSD502TM's prospects, while also providing a compelling premium of more than 38% to the price at which Plethora's last issued shares in August 2014 and we believe it will create significantly more future value than Plethora could achieve independently," Mellon added.

Michael Wyllie, chief science officer at Plethora, said the deal presents an "achievable solution to its difficult financial position whilst providing shareholders an opportunity to maintain an ongoing economic interest in Plethora and its product".

By Samuel Agini; samagini@alliancenews.com; @samuelagini

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
13 Jul 2010 07:28

Plethora Solutions Sees 1H In Line With Market Views, Revenue GBP1M

LONDON (Dow Jones)--Plethora Solutions Holdings PLC (PLE.LN), the U.K.-based specialty pharmaceutical company, said Tuesday first half earnings are expected to be in line with analyst expectations with revenue for the six months ended June 30 of GBP1.0 million and of GBP1.4 million. MAIN FACTS:

Read more
30 Jun 2010 09:30

UK SMALLCAP ROUNDUP: Scott Wilson Bidder URS Gets Deadline

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps SCOTT WILSON GROUP PLC (SWG.LN), a U.K. engineering consultant, Wednesday said its board will give its recommendation to shareholders on the company's bi

Read more
30 Jun 2010 07:48

Plethora Solutions Gets GBP1 Mln Loan For Urology Business

LONDON (Dow Jones)--Drug company Plethora Solutions Holdings PLC (PLE.LN) Wednesday said it has agreed a GBP1 million, five-year secured term loan from a government fund which will be used to speed the roll-out of its specialty pharmaceutical business. The firm said The Urology Company, which it

Read more
5 May 2010 12:52

Small caps round-up: Global Brands, Japan Leisure, Plethora...

Shares in Global Brands charged forward as the Domino's Pizza franchise holder in Switzerland reported strong trading in 2010 to follow a good end to 2009. Global says January sales increased 7.4% on January 2009, February sales increased 11.2%, March sales increased 14.5% and April sales increased

Read more
9 Mar 2010 09:51

Small caps round-up: Ark Therapies, Pangea, Shore Capital ...

Shares in Ark Therapies fell back after the drug developer said it would consider approaches it has received following a recommendation that a further clinical trial would be needed before its brain cancer treatment Cerepro could be approved. Shares in Pangea Diamonds sparkled after the diamond pro

Read more
30 Nov 2009 07:37

Small caps round-up: SDI Group, First Property, Beowulf...

SDI swung into the black at the half-way stage, although the automated warehousing systems firm said the outlook remains "tough". There was a profit of £305,000 in the six months to 30 September versus a loss of £2.6m in the half year to 31 May 2008 (the year end has now moved from November to Marc

Read more
23 Nov 2009 13:17

Small cap round-up: Entertainment One, Plethora, Goldstone...

Film distributor Entertainment One reports record takings for the UK and Canadian opening of The Twilight Saga: New Moon, the sequel to the 2008 box office hit Twilight. New Moon, a film about vampires, has already generated an estimated weekend box office of more than £11m in the UK and $11m in C

Read more
17 Sep 2009 08:39

Small caps round-up: Byotrol, ReNeuron, Accuma...

Germ-killing product supplier Byotrol said it has seen a significant increase in orders and now expects results for the financial year to September 30 to be ahead of expectations. Shares in Meridian Petroleum gushed higher after the oil and gas firm announced an increase in prospective resources in

Read more
29 Jul 2009 08:15

Plethora reports PSD502 trial success

Plethora Solutions has moved closer to global approval for its PSD502 premature ejaculation treatment for men after a final US phase 3 trial met all of its objectives. This study, involving patients from the US, Canada and Europe, was one of two pivotal Phase III studies for PSD502, which were run

Read more
26 May 2009 07:57

Plethora sells rights to key product

Drug developer Plethora has sold the rights of its key PSD502 premature ejaculation product to Sciele Pharma to cut its debts and pay back venture capital financing. Under the terms of the agreement, Sciele will make additional upfront payments of $8.4m and also share development costs for PSD502 f

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.